Plasma pT181-Tau is not an established diagnostic biomarker for Alzheimer’s disease, but it could become one in the future, or it may serve as a screening tool for specific cases of patients or presymptomatic subjects. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.